Alzheimer’s Drug Trial Fails
February 11, 2020
In a major international trial, two experimental drugs designed to fight brain plaques widely linked to Alzheimer’s disease have failed to stop the cognitive decline characteristic of the disorder—a result a team leader called “really crushing.” But perhaps not surprising. In Issues recently, a policy analyst recounted the poor track record of other Alzheimer’s drug candidates, stressing that “innovation has mostly been in patient care, not biomedical advance,” and a philanthropy leader argued that it is time to focus on “new directions in aging and neurodegeneration research.”